Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, November 29, 2012
Atossa Genetics, Inc. to Present at the 5th Annual LD Micro Conference
November 29, 2012 08:30 ET
Atossa Genetics, Inc. to Present at the 5th Annual LD Micro Conference
SEATTLE, WA--(Marketwire - Nov 29, 2012) - [ Atossa Genetics, Inc ]. (
Dr. Quay's presentation will focus on the Company's novel approaches to breast cancer risk assessment and prevention, 2013 growth initiatives for its first year as a public company, and its unique investment thesis.
A [ link ] to the live audio webcast with slides of the presentation can be accessed on Atossa's website. After clicking on the webcast [ link ], visitors will be directed to the proper conference's registration page. After completing the required fields and clicking "Register," visitors will then be brought to the dedicated webcast page. A replay of the webcast will be available for 90 days after the presentation and can be accessed at the same web address.
The LD Micro Conference is a two-day conference organized by LD Micro, a by-invitation only newsletter firm that provides micro-cap research for its clients. The LD Micro Conference focuses on undervalued micro-cap companies in a broad range of industries. A record 580 investors attended the 2011 event. Investors interested in attending the conference should call 408-457-1042 or e-mail [ Chris@ldmicro.com ], or visit the [ conference website ].
About Atossa Genetics, Inc.
[ Atossa Genetics, Inc. ], The Breast Health Company™, is based in Seattle, Washington, and is focused on preventing breast cancer through the commercialization of patented, FDA-cleared diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect [ precursors to breast cancer ] up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
[ The National Reference Laboratory for Breast Health (NRLBH) ], a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, Washington, that provides the patented [ ForeCYTE Breast Health Test ], a risk assessment test for women 18 to 73 years of age akin to the [ Pap Smear ] and the [ ArgusCYTE Breast Health Test ], a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
